tasigna.com

Tasigna - Home

This site is intended for Healthcare Professionals outside the U.S. Summary of Product Characteristics. This is an international site for TASIGNA (Nilotinib) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country. The Tasigna Daily Plan...

http://www.tasigna.com/

OVERVIEW OF tasigna.com

TRAFFIC RANK

>1,000,000

REVIEWS

0

PAGES IN THIS WEBSITE

10

LINKS TO THIS WEBSITE

CONTACTS

ADDRESSES

SOCIAL LINKS

ONLINE SINCE

WEBSITE DETAILS

SEO

PAGES

SIMILAR SITES

TRAFFIC RANK FOR TASIGNA.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

August

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Tuesday

TRAFFIC BY CITY

Sign up

CUSTOMER REVIEWS

Average Rating: 4.1 out of 5 with 13 reviews

5 star

5

4 star

6

3 star

1

2 star

0

1 star

1

Hey there! Start your review of tasigna.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

LOAD TIME

3.5 seconds

CONTACTS AT TASIGNA.COM

Novartis AG

Domain Admin

P.O. B●●●●●●-4002,

Ba●●el , 4002

CH

1.20●●●●5740

1.20●●●●5799

no●●●●●●●●●●●●●●@markmonitor.com

View this contact

MarkMonitor, Inc.

Domain Admin

391 N. ●●●●●●● Place,

Bo●●se , ID, 83704

US

1.20●●●●5740

1.20●●●●5799

no●●●●●●●●●●●●●●@markmonitor.com

View this contact

MarkMonitor, Inc.

Domain Admin

391 N. ●●●●●●● Place,

Bo●●se , ID, 83704

US

1.20●●●●5740

1.20●●●●5799

no●●●●●●●●●●●●●●@markmonitor.com

View this contact

ADD CONTACT

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

DOMAIN REGISTRATION INFORMATION

REGISTERED: 2003 November 25
UPDATED: 2014 July 18
EXPIRATION: EXPIRED REGISTER THIS DOMAIN

BUY YOUR DOMAIN

DOMAIN AGE

21

YEARS
6

MONTHS
3

DAYS

NAME SERVERS

1: dns1.novartis.com
2: dns2.novartis.com
3: mia03.digex.com

REGISTRAR

MARKMONITOR INC.

WHOIS : whois.markmonitor.com

REFERRED : http://www.markmonitor.com

CONTENT

PAGES IN
THIS WEBSITE

10

SSL

EXTERNAL LINKS

37

SITE IP

217.114.93.50

LOAD TIME

3.469 sec

SCORE

6.2

PAGE TITLE

Tasigna - Home | tasigna.com Reviews

<META> DESCRIPTION

This site is intended for Healthcare Professionals outside the U.S. Summary of Product Characteristics. This is an international site for TASIGNA (Nilotinib) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country. The Tasigna Daily Plan...

<META> KEYWORDS

1 us residents

2 safety information

3 print

4 ph cml overview

5 mechanism of action

6 tasigna clinical studies

7 efficacy

8 earlier responses

9 deeper responses

10 fewer progressions

CONTENT

Page content here

KEYWORDS ON PAGE

us residents,safety information,print,ph cml overview,mechanism of action,tasigna clinical studies,efficacy,earlier responses,deeper responses,fewer progressions,switch to tasigna,safety,enestnd safety data,warnings/ precautions,prescribing,tasigna dosing

SERVER

Microsoft-IIS/8.0

POWERED BY

ASP.NET

CONTENT-TYPE

utf-8

GOOGLE PREVIEW

Tasigna - Home | tasigna.com Reviews

https://tasigna.com

This site is intended for Healthcare Professionals outside the U.S. Summary of Product Characteristics. This is an international site for TASIGNA (Nilotinib) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country. The Tasigna Daily Plan...

SUBDOMAINS

us.tasigna.com

Home Page

For US. Residents Only. Non–U.S. Residents. How to take TASIGNA. Learn How TASIGNA Works. What is Chronic Myeloid Leukemia? Treating Your Ph CML. Talking to Your Doctor. Learn about the TASIGNA Dual Offer Card. Register for a TASIGNA Support Program. Reimbursements and Other Assistance. Online Ph CML Resources. Visit our Facebook page. Introducing the TASIGNA Dual Offer Card. Up to 3 months free for all patients new to TASIGNA. 0 copay offer for commercially insured patients. How to take TASIGNA. Newly d...

INTERNAL PAGES

tasigna.com

1

Chronic Myeloid Leukaemia Overview

http://www.tasigna.com/ph_cml_overview.html

This site is intended for Healthcare Professionals outside the U.S. Summary of Product Characteristics. Ph CML Disease Overview. Philadelphia chromosome-positive chronic myeloid leukemia (Ph CML) is a disease caused by an abnormal fusion protein, BCR-ABL. Ph CML is a myeloproliferative disease characterized by the presence of the abnormal Philadelphia chromosome in hematopoietic stem cells. The Philadelphia chromosome results from a reciprocal translocation of sections of chromosomes 9 and 22. ENESTnd is...

2

Early Molecular Response (EMR) vs Imatinib | Tasigna (nilotinib)

http://www.tasigna.com/earlier_responses.html

This site is intended for Healthcare Professionals outside the U.S. Summary of Product Characteristics. More Patients Achieved Early Molecular Response With TASIGNA (nilotinib) vs Imatinib. ELN has defined optimal response milestones in newly diagnosed patients with Ph CML-CP. At 3 months the recommended optimal response is BCR-ABL. 10%, also referred to as EMR. In retrospective analysis of ENESTnd evaluating EMR at 3 months, more patients achieved EMR with TASIGNA. In patients on TASIGNA or imatinib.

3

Tasigna (nilotinib) Mechanism of Action

http://www.tasigna.com/mechanism_of_action.html

This site is intended for Healthcare Professionals outside the U.S. Summary of Product Characteristics. TASIGNA (nilotinib) Mechanism of Action. BCR-ABL is the key cause and driver of Philadelphia chromosome-positive chronic myeloid leukemia (Ph CML). Because BCR-ABL is a key cause of Philadelphia chromosome-positive chronic myeloid leukemia (Ph CML) and remains the driver of the disease throughout the chronic phase, BCR-ABL inhibition is the focus of CML treatment. Hochhaus A, et al. Leukemia. 2...Shah ...

4

CML Major Molecular Reponse

http://www.tasigna.com/major_molecular_response.html

This site is intended for Healthcare Professionals outside the U.S. Summary of Product Characteristics. MMR Has Significant Prognostic Value for Patients With CML. Achievement of MMR is associated with higher rates of EFS. Durable MMR is associated with improved PFS. 7-year EFS according to molecular response at 12 months. Achieving MMR is associated with improved clinical outcomes. Cytogenetic testing lacks the sensitivity to identify MMR achievement. Radich JP. Blood. 2009;114(16):3376-3381;.

5

Chronic Myeloid Leukaemia (CML) ELN Treatment Guidelines

http://www.tasigna.com/eln_recommendations.html

This site is intended for Healthcare Professionals outside the U.S. Summary of Product Characteristics. Monitoring CML Treatment Response. For patients receiving long-term therapy for Philadephia chromosome-positive chronic myeloid leukemia (Ph CML), ongoing monitoring is needed to assess whether they have achieved or are making progress toward a desired response to therapy and to ensure that their treatment is optimized over time. At least 20 meta phases must be counted. Measures BCR-ABL transcript leve...

UPGRADE TO PREMIUM TO VIEW 5 MORE

TOTAL PAGES IN THIS WEBSITE

10

LINKS TO THIS WEBSITE

hematologymarketinsights.blogspot.com

Hematology Competitive Insights: Second-line treatment in CML

http://hematologymarketinsights.blogspot.com/2008/07/second-line-treatment-in-cml.html

Tuesday, July 29, 2008. Second-line treatment in CML. MD Anderson Cancer Center recently published a new article in Blood. Looking at second-line treatment with tyrosine kinase therapies with nilotinib. Failure. This is a crucial question - how long should patients receive their new therapy before considering alternative treatments? Thanks for this useful post. Here is some additional information about the genetics of this condition that was written by our Genetic Counselor and other genetic professi...

panoproviderportaldemo.com

PANO Provider Portal

https://www.panoproviderportaldemo.com/Security/ForgotPasswordEmail.aspx

Wednesday, August 31, 2016. Please protect the confidentiality of your patients by not revealing or sharing login credentials. To register for online services, click here:. Call 888-903-7277 for Exjade. 800-282-7630 for all other products. Exjade (deferasirox) tablets for oral suspension. Exjade Prescribing Information, Including Boxed Warning. Gleevec (imatinib mesylate) tablets. Sandostatin LAR (octreotide acetate for injectable suspension). Tasigna Prescribing Information, Including Boxed Warning.

us.tasigna.com

Ph+ CML Treatment | About Tasigna (nilotinib)

http://www.us.tasigna.com/patient/about.jsp

Novartis Pharmaceuticals Corporation has updated the Privacy Policy for this website. Among other changes, the new policy explains how it applies when we communicate with you on different devices and through different services, and how your information helps us personalize your online experiences. To read our new policy. Full Prescribing Information Including Boxed WARNING. Important Safety Information Including Boxed Warning and Indications. Non–U.S. Residents. How Effective is TASIGNA? Learn more about...

us.tasigna.com

Ph+ CML Treatment | About Tasigna (nilotinib)

http://www.us.tasigna.com/patient/safety-information.jsp

Novartis Pharmaceuticals Corporation has updated the Privacy Policy for this website. Among other changes, the new policy explains how it applies when we communicate with you on different devices and through different services, and how your information helps us personalize your online experiences. To read our new policy. Full Prescribing Information Including Boxed WARNING. Important Safety Information Including Boxed Warning and Indications. Non–U.S. Residents. How Effective is TASIGNA? Learn more about...

hematologymarketinsights.blogspot.com

Hematology Competitive Insights: CML - Gleevec or a take a chance on a transplant?

http://hematologymarketinsights.blogspot.com/2008/10/brick-walls-are-not-there-to-keep-us.html

Wednesday, October 1, 2008. CML - Gleevec or a take a chance on a transplant? 8220;The brick walls are not there to keep us out. The brick walls are there to give us a chance to show how badly we want something. Because the brick walls are there to stop the people who don’t want it badly enough. They’re there to stop the other people.”. Which led me to wonder what will happen for patients with chronic myeloid/myelogenous leukemia. What would you do if it was you or a family member? Pharmaceuticals, biote...

UPGRADE TO PREMIUM TO VIEW 32 MORE

TOTAL LINKS TO THIS WEBSITE

37

OTHER SITES

tasigiannis.com

mariavlahoulis

tasigli.com

Tasigli.Com | תשיג לי - מוצרים ישראלים לישראלים בחו"ל

Tasigli.Com תשיג לי – מוצרים ישראלים לישראלים בחול. Israeli products for Israelis abroad מוצרים ישראלים לישראלים בחול. Food & Beverage. Natural & Organic. Pasta & Couscous. Coffee & Tea. Juices & Syrups. Cooking & Baking. Snacks & Cookies. Nuts & Seeds. Pharma & Babies. Spa & Beauty. Over the Counter Drugs. Culture & Fun. T-Shirts & Hats. Magazines & Crosswords. Jordan Valley, Judea & Samaria. No products in the cart. On Sale This Month. VIEW ALL OUR PRODUCTS. Materna Mehadrin Stage 3. Hi, the package ar...

tasigmacats.com

=^..^= TASIGMA =^..^= himalayans cats =^..^=

Last update - 24.April 2013.

tasigna-planner.com

Tasigna Daily Planner

Choose your clock preference. Not intended for use in the US. Your Personal Information is not collected by Novartis during your use of this application. This application contains no cookies or other tracking devices except those necessary for the functioning of application. We do not permit our business partners to make use of or share your information for their own separate marketing purposes. Application Terms of Use. When you Use the Application and the Content, you are solely responsible for:. Any d...

tasigna.cn

更深缓解更少进展 Tasigna中国官方网站- | 达希纳慢粒 CML CML治疗格列卫耐药格列卫不耐受第二代TKI | 网站首页

用于对既往治疗包括伊马替尼耐药或不耐受的费城染色体阳性的慢性髓性白血病 CML 慢性期或加速期成人患者。 MCC Code:TAS1508119(2015-08-13) 2015 Novartis AG. 药监局备案号京 -非经营性-2013- 0069.

tasigna.com

Tasigna - Home

This site is intended for Healthcare Professionals outside the U.S. Summary of Product Characteristics. This is an international site for TASIGNA (Nilotinib) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country. The Tasigna Daily Plan...

tasigna.com.cn

更深缓解更少进展 Tasigna中国官方网站- | 达希纳慢粒 CML CML治疗格列卫耐药格列卫不耐受第二代TKI | 网站首页

用于对既往治疗包括伊马替尼耐药或不耐受的费城染色体阳性的慢性髓性白血病 CML 慢性期或加速期成人患者。 MCC Code:TAS1508119(2015-08-13) 2015 Novartis AG. 药监局备案号京 -非经营性-2013- 0069.

tasigna.nl

Tasigna

De website www.tasigna.nl is momenteel in ontwikkeling. In de toekomst zult u hier meer informatie vinden. Uw toegang tot en gebruik van deze site is onderworpen aan onze disclaimer. 2011 Novartis Pharma BV.

tasignaglobalonlinetoolkit.com

Tasigna Global Online Toolkit

Press Releases and Q&As. Fact Sheets and Backgrounders. Welcome to the Tasigna Global Online Toolkit. To help support local market activities around Tasigna First-line milestones in your countries, this site provides you with press materials, background documents and practical communications materials to help make your campaign a success. Press Releases and Q&As. Fact Sheets and Backgrounders. Internal Guides for Tactical Implementation and Key Primary References.

tasignakd.com

Tasigna

This information is for internal use only, and is not to be left with, detailed from,. Or shown to anyone outside of Novartis Pharmaceuticals Corporation.

tasignasurvey.com

Message

Friday, August 14, 2015. Version: 1.1.0(1.3.2).